Bupropion as a promising approach to rapid cycling bipolar II patients.

摘要: Bupropion was added to lithium and/or levothyroxine in four female and two male bipolar II patients who had established baselines of at least 2 years rapid cycling that not responded several the most commonly used anticycling interventions. Although all six improved significantly, response dramatic (three female, one male) is still sustained after an average continued treatment. Furthermore, unlike what happened their prior course with more conventional antidepressants, none developed hypomania nor observed during pharmacotherapy. These findings, based on open but systematic clinical observation, suggest bupropion may have special merit for cycling, predominantly depressed that, under close vigilance, combining appropriate doses both efficacious safe.